A detailed history of First Horizon Advisors, Inc. transactions in Ligand Pharmaceuticals Inc stock. As of the latest transaction made, First Horizon Advisors, Inc. holds 32 shares of LGND stock, worth $2,713. This represents 0.0% of its overall portfolio holdings.

Number of Shares
32
Holding current value
$2,713
% of portfolio
0.0%

Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 26, 2024

BUY
$68.64 - $89.2 $2,196 - $2,854
32 New
32 $2,000
Q2 2022

Aug 02, 2022

BUY
$74.52 - $117.06 $521 - $819
7 New
7 $0
Q3 2020

Nov 12, 2020

SELL
$89.56 - $126.72 $537 - $760
-6 Closed
0 $0
Q2 2020

Jul 31, 2020

SELL
$68.28 - $123.65 $477 - $865
-7 Reduced 53.85%
6 $0
Q1 2020

May 05, 2020

SELL
$63.37 - $107.88 $9,632 - $16,397
-152 Reduced 92.12%
13 $0
Q3 2019

Oct 23, 2019

SELL
$86.25 - $120.16 $5,692 - $7,930
-66 Reduced 28.57%
165 $16,000
Q2 2019

Aug 05, 2019

BUY
$107.38 - $129.34 $24,804 - $29,877
231 New
231 $0

Others Institutions Holding LGND

About LIGAND PHARMACEUTICALS INC


  • Ticker LGND
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 16,882,800
  • Market Cap $1.43B
  • Description
  • Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...
More about LGND
Track This Portfolio

Track First Horizon Advisors, Inc. Portfolio

Follow First Horizon Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Horizon Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on First Horizon Advisors, Inc. with notifications on news.